Femara 2.5mg 30 tablets — Made in Switzerland — Free Delivery

Brand: NOVARTIS
Product Code: Femara
Availability: In Stock

$87.46

Add to Cart

Description

Product description

Femara® tablets are used for the following indications:

adjuvant therapy of hormone-positive invasive breast cancer in the early stages in postmenopausal women;
extended adjuvant therapy for early invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years;
first-line therapy for hormone-dependent advanced breast cancer in postmenopausal women;
treatment of common forms of breast cancer in postmenopausal women (natural or induced) after relapse or progression of the disease, who received prior antiestrogen therapy;
neoadjuvant therapy in postmenopausal women with hormone-positive, HER-2-negative breast cancer who are not suitable for chemotherapy and are not indicated for urgent surgery.

The effectiveness of the preparation for patients with hormone-negative breast cancer has not been proven.

Compound

The active ingredient is letrozole (one tablet contains 2.5 mg of letrozole).

Excipients: colloidal anhydrous silicon dioxide; microcrystalline cellulose; lactose monohydrate; magnesium stearate; corn starch; sodium starch glycolate (type A); hydroxypropyl methylcellulose; polyethylene glycol 8000; talc; titanium dioxide (E 171) iron oxide yellow (E 172).

Contraindications

hypersensitivity to the active substance or to any other component of the preparation;

endocrine status characteristic of the premenopausal period;

pregnancy, lactation period;

reproductive age of the patient.

Mode of application

Adults, including elderly patients. The recommended dose of Femara® is 2.5 mg once a day. In adjuvant and extended adjuvant therapy, treatment with Femara® should be continued for 5 years or until a relapse of the disease occurs. Patients with metastases should be treated with Femara® until signs of disease progression become apparent. In the context of adjuvant treatment, the possibility of using a sequential therapy regimen should also be considered (letrozole for 2 years, followed by a switch to tamoxifen for 3 years).

In conditions of neoadjuvant treatment, therapy with Femara® should be continued for 4-8 months in order to achieve optimal tumor reduction. If the response to treatment is insufficient, therapy with Femara® should be discontinued and planned surgery should be prescribed and / or further treatment options should be discussed with the patient.

For elderly patients, dose adjustment of the preparation is not required.

Method of use

The preparation "Femara®" should be taken orally, regardless of food intake, since food does not affect the degree of absorption.

The missed dose should be taken as soon as the patient remembers it. However, if the patient remembers this shortly before taking the next dose (2-3 hours), the missed dose should be skipped and the next dose should be taken according to the schedule. Do not take a double dose, because when taking a daily dose that is higher than the recommended 2.5 mg, a systemic exposure was observed that was higher than the proportional one.

Application features

Children

The preparation is not used in children, since the efficacy and safety of the preparation in this category of patients have not been studied in clinical trials.

Drivers

The effect of Femara® on the ability to drive vehicles and work with other mechanisms is insignificant. Since during the treatment with the preparation in patients, general weakness and dizziness were observed, as well as in some cases drowsiness, caution is recommended when driving vehicles and working with mechanisms.

Overdose

Reported isolated cases of overdose of the preparation "Femara".

The specific treatment for overdose is unknown; treatment should be symptomatic and supportive.

Side effects

In general, the adverse reactions that were observed were predominantly mild or moderate in nature and in most cases were associated with estrogen deficiency. The most common adverse reactions reported in clinical study reports were hot flashes, hypercholesterolemia, arthralgia, nausea, increased sweating, and fatigue. Important additional adverse reactions that may develop during treatment with Femara® include such phenomena from the musculoskeletal system as osteoporosis and / or bone fractures, and phenomena from the cardiovascular system (including cerebrovascular and thromboembolic events).

Storage conditions

Store in its original packaging to protect from moisture at a temperature not exceeding 30 ° C, out of the reach of children.

The shelf life is 5 years.

0 reviews

There are no reviews for this product.